Press release
Cholangiocarcinoma Market Forecast 2034: Clinical Trials, Treatment Market, Medication, EMA, PDMA, FDA Approvals, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight
Cholangiocarcinoma Market
(Albany, USA) DelveInsight's "Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cholangiocarcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cholangiocarcinoma market.
Request for a Free Sample Report @ Cholangiocarcinoma Market Forecast [https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Cholangiocarcinoma Market Report are:
* According to DelveInsight, Cholangiocarcinoma market size is expected to grow at a decent CAGR by 2034.
* In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2020-2034).
* Leading Cholangiocarcinoma companies working in the market are AstraZeneca, Decalth Systems, Power Life Sciences, Genfit, Servier Affaires Medicales, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and Others.
* Key Cholangiocarcinoma Therapies expected to launch in the market are PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), and others.
* In April 2025, Servier (Servier Affaires Medicales) announced an Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
* In February 2025, Eisai Inc. announced results of a Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion
* In January 2025, Servier announced results of a Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
* In December 2024, Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company revolutionizing drug discovery through advanced computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. focused on improving treatment outcomes for patients with limited therapeutic options, announced today an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The partnership follows Relay's recent positive FDA interaction and previously reported promising data in cholangiocarcinoma and other solid tumors.
* In September 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.
* On March 2024, Genfit announced an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy.
* On Feb 2024, TransThera Sciences (Nanjing), Inc announced a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
* On March 2023, Power Life Sciences Inc announced a Clinical Study Experiences of Cholangiocarcinoma Patients to Identify Trial Attributes Affecting Completion Rates for Specific Demographic Groups.
Learn more about Cholangiocarcinoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Cholangiocarcinoma Overview
Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts, which transport bile from the liver to the small intestine. This cancer is classified into three types based on its location: intrahepatic (within the liver), perihilar (at the liver's hilum), and distal (further down the bile duct). The majority of cholangiocarcinomas are adenocarcinomas, which arise from the mucus glands in the bile duct.
Risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic liver disease, bile duct cysts, liver flukes, and certain genetic conditions. Symptoms often appear late and may include jaundice, abdominal pain, weight loss, and itching, making early detection challenging.
Diagnosis typically involves imaging studies such as MRI, CT scans, and cholangiography, along with biopsy and blood tests. Treatment options vary depending on the cancer's stage and location but may include surgery, radiation therapy, chemotherapy, and targeted therapies. Liver transplantation is an option for some patients with early-stage disease.
Despite advances in treatment, the prognosis for cholangiocarcinoma remains poor, emphasizing the need for ongoing research and improved therapeutic strategies. Early diagnosis and multidisciplinary care are crucial for enhancing patient outcomes.
Request for Sample Report @ [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Cholangiocarcinoma Market
The Cholangiocarcinoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholangiocarcinoma market trends by analyzing the impact of current Cholangiocarcinoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Cholangiocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cholangiocarcinoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Cholangiocarcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.
Cholangiocarcinoma Epidemiology
The Cholangiocarcinoma epidemiology section provides insights into the historical and current Cholangiocarcinoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cholangiocarcinoma market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Cholangiocarcinoma Epidemiology @ Cholangiocarcinoma Market Dynamics and Trends [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr]
Cholangiocarcinoma Drugs Uptake
This section focuses on the uptake rate of the potential Cholangiocarcinoma drugs recently launched in the Cholangiocarcinoma market or expected to be launched in 2020-2034. The analysis covers the Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Cholangiocarcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Cholangiocarcinoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cholangiocarcinoma Therapies and Key Companies
* PEMAZYRE (pemigatinib): Incyte
* TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceutical
* LYTGOBI (futibatinib): Taiho Pharma
* Imfinzi (durvalumab): Astrazeneca
* Melphalan: Decalth Systems
* Derazantinib: Basilea Pharmaceuticals
* Futibatinib (TAS-120): Taiho Oncology
* E7090: Eisai Pharmaceuticals
* TT-0040: TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma Pipeline Development Activities
The Cholangiocarcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cholangiocarcinoma key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Cholangiocarcinoma pipeline development activities @ [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Cholangiocarcinoma Therapeutics Assessment
Major key companies are working proactively in the Cholangiocarcinoma Therapeutics market to develop novel therapies which will drive the Cholangiocarcinoma treatment markets in the upcoming years are AstraZeneca (LSE: AZN), Decalth Systems (Private), Power Life Sciences (Private), Genfit (EPA: GNFT), Servier Affaires Medicales (Private), Basilea Pharmaceutica (SWX: BSLN), Taiho Oncology (Private), Eisai Pharmaceuticals (TYO: 4523), TransThera Sciences (Private), Incyte Corporation (NASDAQ: INCY), Roche (SWX: ROG), Agios Pharmaceuticals (NASDAQ: AGIO), Servier Pharmaceuticals (Private), and others.
Cholangiocarcinoma Report Key Insights
1. Cholangiocarcinoma Patient Population
2. Cholangiocarcinoma Market Size and Trends
3. Key Cross Competition in the Cholangiocarcinoma Market
4. Cholangiocarcinoma Market Dynamics (Key Drivers and Barriers)
5. Cholangiocarcinoma Market Opportunities
6. Cholangiocarcinoma Therapeutic Approaches
7. Cholangiocarcinoma Pipeline Analysis
8. Cholangiocarcinoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Cholangiocarcinoma Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Cholangiocarcinoma Competitive Intelligence Analysis
4. Cholangiocarcinoma Market Overview at a Glance
5. Cholangiocarcinoma Disease Background and Overview
6. Cholangiocarcinoma Patient Journey
7. Cholangiocarcinoma Epidemiology and Patient Population
8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Cholangiocarcinoma Treatment
11. Cholangiocarcinoma Marketed Products
12. Cholangiocarcinoma Emerging Therapies
13. Cholangiocarcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Cholangiocarcinoma Market Outlook (7 major markets)
16. Cholangiocarcinoma Access and Reimbursement Overview
17. KOL Views on the Cholangiocarcinoma Market
18. Cholangiocarcinoma Market Drivers
19. Cholangiocarcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cholangiocarcinoma-market-forecast-2034-clinical-trials-treatment-market-medication-ema-pdma-fda-approvals-epidemiology-nice-approvals-therapies-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cholangiocarcinoma Market Forecast 2034: Clinical Trials, Treatment Market, Medication, EMA, PDMA, FDA Approvals, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight here
News-ID: 4028277 • Views: …
More Releases from ABNewswire
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced…
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY…
Applications of 5-50mm security camera lens
The application scenarios of 5-50 mm surveillance lenses are primarily categorized according to the variations in field of view resulting from changes in focal length. The specific applications are as follows:
1. Wide-angle range (5-12 mm)
Panoramic monitoring for confined spaces A focal length of 5-8 mm (with a field of view of 60 degrees -90 degrees ) is suitable for enclosed small areas within 5 times 5 meters, such as elevator…
Daniel Smart Manufacturing Empowers Riders with their New Custom Builder Feature …
A leather jacket [https://danielsmartmfg.com/collections/mens-leather-motorcycle-jackets] for a rider is an essential part of their ride, and it makes them feel incomplete without it whenever they hit the road. If you are a biker, you must know what it means. Now imagine you can design your leather jacket your way, which may further enhance your experience on the road. Well, Daniel Smart, a renowned brand in the leather jacket industry, is now…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma…
